The most interesting thing for me is that despite all the...

The most interesting thing for me is that despite all the denials and former management screaming blue murder, that BLA needs a black knight demonstrates that Glaucus was right all along. The fact that they need a $50m capital injection just to keep on going precisely proves the point that the business model was broken, it's just that nobody realised it, except for a couple of other short seller research houses who got hit with threats of litigation from BLA.

The other interesting thing is that the share price is now down to less than half Glaucus' original target of $2.66.